(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
13 August 2015 (13.08.2015)

WIPO | PCT

(10) International Publication Number
WO 2015/119495 A1

(51) **International Patent Classification**:
A61K 31/506 (2006.01) *A61P 9/00* (2006.01)
A61P 3/06 (2006.01)

(21) **International Application Number**:
PCT/NL2014/050068

(22) **International Filing Date**:
5 February 2014 (05.02.2014)

(25) **Filing Language**: English

(26) **Publication Language**: English

(71) **Applicants**: **DEZIMA PHARMA B.V.** [NL/NL]; Gooimeer 2-35, NL-1411 DC Naarden (NL). **MITSUBISHI TANABE PHARMA CORPORATION** [JP/JP]; 3-2-10, Dosho-machi, Chuo-ku, Osaka-shi, Osaka 541-8505 (JP).

(72) **Inventors**: **FORD, John**; 50 High Street, Hemingford Grey, Cambridgeshire PE 28 9BJ (GB). **ROUND, Patrick**; 6, Glanely Gardens, Exning Newmarket, Suffolk CB87PA (GB). **KASTELEIN, John**; Afroditekade 244, NL-1076 DZ Amsterdam (NL). **KAWAGUCHI, Atsuhiro**; c/o Mitsubishi Tanabe Pharma Corporation, 2-6-18, Kitahama, Chuo-ku, Osaka-shi, Osaka, 541-8505 (JP). **TOMIYASU, Koichi**; c/o Mitsubishi Tanabe Pharma Corporation, 2-6-18, Kitahama, Chuo-ku, Osaka-shi, Osaka, 541-8505 (JP). **OKA, Kozo**; c/o Mitsubishi Tanabe Pharma Corporation, 2-6-18, Kitahama, Chuo-ku, Osaka-shi, Osaka, 541-8505 (JP).

(74) **Agent**: **NEDERLANDSCH OCTROOIBUREAU**; J.W. Frisolaan 13, 2517 JS The Hague (NL).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

WO 2015/119495 A1

(54) **Title**: CHOLESTERYL ESTER TRANSFER PROTEIN (CETP) INHIBITOR AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAID INHIBITOR FOR USE IN THE TREATMENT OR PREVENTION OF CARDIOVASCULAR DISEASES

(57) **Abstract**: The present invention relates to a cholesteryl ester transfer protein (CETP) inhibitor for use in the treatment of subjects suffering from or having an increased risk for cardiovascular diseases, in particular hyperlipidemia or mixed dyslipidemia. A further aspect of the present invention relates to a pharmaceutical composition for use in the treatment of subjects suffering from or having an increased risk for cardiovascular diseases, wherein the composition comprises a therapeutically effective amount of said CETP inhibitor.